Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.

Anatoli Slepenkin, Sukumar Pal, Amy Rasley, Matthew A Coleman, Luis M de la Maza

Abstract read

In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Presentation of the protective epitope in a Chlamydia muridarum MOMP vaccine is dependent on γ-interferon-inducible lysosomal thiol reductase (GILT).ImmunoHorizons · 2026
Article
Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.Iranian journal of basic medical sciences · 2025
Article
Cell-Free Screening, Production and Animal Testing of a STI-Related Chlamydial Major Outer Membrane Protein Supported in Nanolipoproteins.Vaccines · 2024
Article

4 · The record

Corrections and comments

Update of
Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum respiratory challenge.2023

5 · Who and what money

Authors and funding

5 authors.

Anatoli SlepenkinDepartment of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA, 92697-4800, USA.

Sukumar PalDepartment of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA, 92697-4800, USA.ORCID http://orcid.org/0000-0001-5170-5121

Amy RasleyPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA, 94550-9234, USA.

Matthew A ColemanPhysical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA, 94550-9234, USA.

Luis M de la MazaDepartment of Pathology and Laboratory Medicine, Medical Sciences I, Room D440, University of California, Irvine, Irvine, CA, 92697-4800, USA. Imdelama@uci.edu.ORCID http://orcid.org/0000-0002-6183-7053

Funding

Project 1. Nanolipoprotein-supported multi-subunit vaccine for Chlamydia trachomatisU19AI144184 · NIAID · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI COLEMAN, MATTHEW ADRIAN · 2019 to 2023

$10.0M

NIAID NIH HHS U19 AI144184

6 · The paper itself

Abstract

It is recommended that the adjuvant Montanide ISA 720 VG be used at a concentration of 70% v/v. At this concentration, Montanide causes at the site of immunization a local granuloma that can last for several weeks. To determine the safety and protective efficacy of a Chlamydia muridarum MOMP vaccine, formulated with CpG-1826 and four different concentrations of Montanide (70%, 50%, 30% and 10%), BALB/c (H-2

Identifiers

PMID38858418

DOI10.1038/s41541-024-00880-6

PMCPMC11164897

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.